220 related articles for article (PubMed ID: 10732889)
1. Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
Bhatt DL; Marso SP; Lincoff AM; Wolski KE; Ellis SG; Topol EJ
J Am Coll Cardiol; 2000 Mar; 35(4):922-8. PubMed ID: 10732889
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
[TBL] [Abstract][Full Text] [Related]
4. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
Akkerhuis KM; Deckers JW; Lincoff AM; Tcheng JE; Boersma E; Anderson K; Balog C; Califf RM; Topol EJ; Simoons ML
JAMA; 2001 Jul; 286(1):78-82. PubMed ID: 11434830
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
[TBL] [Abstract][Full Text] [Related]
6. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ;
Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986
[TBL] [Abstract][Full Text] [Related]
7. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
8. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
10. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
[TBL] [Abstract][Full Text] [Related]
11. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
Tornvall P; Nilsson T; Lagerqvist B
J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
[TBL] [Abstract][Full Text] [Related]
12. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
13. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
[TBL] [Abstract][Full Text] [Related]
14. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
[TBL] [Abstract][Full Text] [Related]
15. [Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].
Hernández García JM; Domínguez Franco A; Jiménez-Navarro MF; Alonso Briales JH; Curiel Balsera E; Gómez Doblas JJ; De Teresa Galván E
Rev Esp Cardiol; 2002 Aug; 55(8):810-5. PubMed ID: 12199976
[TBL] [Abstract][Full Text] [Related]
16. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
[TBL] [Abstract][Full Text] [Related]
17. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Ibbotson T; McGavin JK; Goa KL
Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
[TBL] [Abstract][Full Text] [Related]
18. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
19. Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention.
Perkan A; Vitrella G; Barbati G; De Monte A; D'Agata B; Merlo M; Giannini F; Della Grazia E; Rakar S; Salvi A; Igidbashian D; Morgera T; Zalukar W; Sinagra G
J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):127-35. PubMed ID: 22343257
[TBL] [Abstract][Full Text] [Related]
20. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]